dc.creator | Kontaki H., Koukaki M., Vasilarou M., Giakountis A., Deligianni E., Luo X., Kim Y., Talianidis I. | en |
dc.date.accessioned | 2023-01-31T08:44:00Z | |
dc.date.available | 2023-01-31T08:44:00Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.isci.2021.102473 | |
dc.identifier.issn | 25890042 | |
dc.identifier.uri | http://hdl.handle.net/11615/75074 | |
dc.description.abstract | The oncogenic function of suppressor of variegation, enhancer of zeste and MYeloid-Nervy-DEAF1-domain family methyltransferase Smyd3 has been implicated in various malignancies, including hepatocellular carcinoma (HCC). Here, we show that targeting Smyd3 by next-generation antisense oligonucleotides (Smyd3-ASO) is an efficient approach to modulate its mRNA levels in vivo and to halt the growth of already initiated liver tumors. Smyd3-ASO treatment dramatically decreased tumor burden in a mouse model of chemically induced HCC and negatively affected the growth rates, migration, oncosphere formation, and xenograft growth capacity of a panel of human hepatic cancer cell lines. Smyd3-ASOs prevented the activation of oncofetal genes and the development of cancer-specific gene expression program. The results point to a mechanism by which Smyd3-ASO treatment blocks cellular de-differentiation, a hallmark feature of HCC development, and, as a result, it inhibits the expansion of hepatic cancer stem cells, a population that has been presumed to resist chemotherapy. © 2021 The Authors | en |
dc.language.iso | en | en |
dc.source | iScience | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105470864&doi=10.1016%2fj.isci.2021.102473&partnerID=40&md5=1fcfb59ac1d38b04405844299481c5de | |
dc.subject | Elsevier Inc. | en |
dc.title | Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth | en |
dc.type | journalArticle | en |